Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Brexi 1
Eskayef Pharmaceuticals Ltd.
Generic: Brexpiprazole
Medicine Overview of Brexi 1mg Tablet
বাংলা
English
Indication
Indicated for schizophrenia, Indicated as adjunctive treatment for major depressive disorder
Administration
May take with or without food
Adult Dose
Schizophrenia Indicated for schizophrenia Recommended starting dose: 1 mg PO qDay on Days 1 through 4 Recommended target dose: 2-4 mg PO qDay; titrate to 2 mg qDay on Days 5 through 7, and then to 4 mg/day on Day 8 based on the patient’s clinical response and tolerability Not to exceed 4 mg/day Periodically reassess to determine the continued need and appropriate dose Depression Indicated as adjunctive treatment for major depressive disorder Recommended starting dose: 0.5 mg or 1 mg PO qDay Recommended target dose: 2 mg PO qDay; at weekly intervals, titrate to 1 mg/day, and then up...
... Show moreRenal Dose
Renal impairment
Moderate, severe, or ESRD (CrCl <60 mL/min)
MDD: Not to exceed 2 mg/day
Schizophrenia: Not to exceed 3 mg/day
Contraindication
Hypersensitivity; reactions have included rash, facial swelling, urticaria, and angioedema
Mode of Action
Serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors
Precaution
Increased mortality in elderly patients with dementia-related psychosis; in placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared with placebo Suicidal thoughts and behaviors reported in children, adolescents, and young adults who are taking antidepressant drugs Potentially fatal neuroleptic malignant syndrome (NMS) reported in association with administration of antipsychotic drugs; if NMS is suspected, immediately discontinue therapy and provide intensive symptomatic treatment and monitoring Potentially irreversible, involuntary, dyskinetic movements (ie, tardive dyskinesia) reported with antipsychotic drugs; incidence highest in...
... Show moreSide Effect
>10%
Akathisia (4-14%)
1-10%
Headache (4-9%)
Weight increased (3-8%)
Nasopharyngitis (1-7%)
Extrapyramidal symptoms, excluding akathisia (5-6%)
Somnolence (4-6%)
Dyspepsia (2-6%)
Constipation (1-6%)
Tremor (2-5%)
Fatigue/sedation (2-5%)
Dizziness (1-5%)
Increased CPK blood levels (2-4%)
Decreased cortisol levels (2-4%)
Anxiety (2-4%)
Restlessness (2-4%)
Increased appetite (2-3%)
Diarrhea (1-3%)
Frequency Unknown
Dystonia
Pregnancy Category Note
Pregnancy Adequate and well-controlled studies have not been conducted with brexpiprazole in pregnant women to inform drug-associated risks; however, neonates whose mothers are exposed to antipsychotic drugs, like brexpiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms (eg, agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder) Animal reproduction studies No teratogenicity was observed with oral administration of brexpiprazole to pregnant rats and rabbits during organogenesis at doses up to 73 and 146 times, respectively, of maximum recommended human dose (MRHD) of 4 mg/day on a mg/m² basis However, when pregnant rats were administered brexpiprazole...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
